Ed Scolnick

Ed Scolnick

Directeur/Bestuurslid bij
Massachusetts Institute of Technology
85 jaar
Health Technology
Commercial Services
Finance

Profiel

Ed M.
Scolnick
is currently the Director at Massachusetts Institute of Technology, and a Member of the National Academy of Sciences, American Academy of Arts & Sciences, and National Academy of Medicine.
He previously served as Director at EMD Millipore Corp., Renovis, Inc., Hypnion, Inc., Link Medicine Corp., and Chiasma, Inc. He was also a Director at Alnylam Pharmaceuticals, Inc. from 2008 to 2010.
Additionally, he served as Senior Vice President-Cell Biology Research at Merck & Co., Inc. from 1982 to 2002, and as President of Merck Research Laboratories Massachusetts LLC from 1982 to 2003.
He was also a Director at the US Food & Drug Administration and National Cancer Institute.
Dr. Scolnick received his undergraduate degree in 1961 and doctorate in 1965 from Harvard University.

Actieve functies van Ed Scolnick

BedrijvenFunctieBegin
Directeur/Bestuurslid -
Corporate Officer/Principal -
Corporate Officer/Principal -
Corporate Officer/Principal -

Eerdere bekende functies van Ed Scolnick

BedrijvenFunctieEinde
Directeur/Bestuurslid 15-07-2010
ALNYLAM PHARMACEUTICALS, INC. Directeur/Bestuurslid 01-02-2010
Private Equity Investor 30-06-2008
Directeur/Bestuurslid 20-07-2005
President 01-01-2003
Ervaring van Ed Scolnick in detail bekijken

Opleiding van Ed Scolnick

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

93

Eerstegraads connecties

17

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit17

Health Technology

Commercial Services

Health Technology

Commercial Services

Health Technology

Health Technology

Finance

Consumer Services

Health Technology

Finance

Health Services

Miscellaneous

Government

Commercial Services

Commercial Services

Commercial Services

Health Technology

  1. Beurs
  2. Insiders
  3. Ed Scolnick
-40 %: uitzonderlijke verlenging
d
:
:
PROFITEER NU